 |
CTSI Updates: Announcement |
|
|
|
|
NIAAA Funds Boston University/Boston Medical Center Investigators to Establish Two New HIV/Alcohol Centers |
Exciting new NIAAA initiative that funds Boston University and Boston Medical Center investigators to establish two new HIV/alcohol centers. It is a step forward to understand how alcohol use impacts people affected by HIV and to develop related interventions. Learn more
|
|
|
|
|
Career Development Award Writing Workshop Series - Spring 2022
Application Deadline: Nov. 19, 2021
Are you planning to submit a Career Development Award? Have you assembled mentors and developed a Specific Aims page, but want to ensure that you submit the most competitive application possible? Learn More
|
Seeking a Co-Director for the KL2
and Workforce Development Programs
Application Deadline: Nov. 30, 2021.
The BU CTSI’s KL2 Program and Workforce Development programs aim to build a system that provides continuous comprehensive mentoring and career development support for scholars from postdoctoral training through early faculty years and to anticipate the skills that scholars will need for future success in research. Learn More
|
Program for Early Research Career Development - Spring 2022
Application Deadline: Dec. 10, 2021
The Program for Early Research Career Development will provide a roadmap and targeted guidance for senior post-doctoral fellows and early career faculty (both MD and PhD) committed to launching an independent research career. Learn More
|
Annual CTSI Regional Shared Mentoring Symposium - Virtual Event
Dec. 10, 2021, 8:30 am - 12:30 pm.
Register before Nov. 10, 2021
This symposium provides networking, panel discussions and one-to-one mentoring
with senior faculty from local clinical and translational science institutions. Learn More
|
The BU CTSI Voucher Program
Applications are Accepted on a Rolling Basis.
The Voucher Program supports the short-term needs of research investigators that are not otherwise covered by grants. Vouchers are intended to enable preliminary work, generate data for new or ongoing projects, and/or secure fee-based core services for expert consultation services. Learn More
|
|
|
|
|
Funding & Fellowship Opportunities |
|
|
|
|
Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)
National Heart, Lung, and Blood Institute (NHLBI)
|
Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
Notice of Special Interest (NOSI): Clinical Characterization and Intervention Strategies for Cancer Therapy Induced Adverse Sequelae
National Cancer Institute (NCI)
|
|
|
|
Notice of Special Interest: Administrative Supplements for NIA-VA Mentored Physician-Scientist Award in Alzheimer’s Disease and Related Dementias (AD/ADRD)
NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice
Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional)
National Institute on Aging (NIA)
|
|
|
|
Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
|
HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
National Center for Complementary and Integrative Health (NCCIH)
|
|
|
|
|
COVID-19 Drug Candidate with Wide-Ranging Antiviral Activity
Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell. Read More
|
|
|
|
|
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
PAXLOVID™ is an investigational SARS-CoV-2 protease inhibitor antiviral therapy, specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure. Read More
|
|
|
|
|
NIH Scientists Identify Mechanism that May Influence Infectivity of SARS-CoV-2 Variants
The outer surface of SARS-CoV-2 is decorated with spike proteins, which the virus uses to attach to and enter cells. Before this can happen, though, the spike protein must be activated by a series of cuts, or cleavages, by host proteins, starting with the furin enzyme
|
|
|
|
|
Networking @ Noon
Nov. 18, 2021, 12 - 1 pm
November's session will discuss the
Community Engagement Core Competency of Appreciation for stakeholder’s experience with and attitudes toward research. Learn More
|
|
|
|
|
Implementation Science Journal Club
Nov. 18, 2021, 1 pm
Join us for the CIIS Implementation Science Journal Club!
CIIS Co-Directors, Drs. Mari-Lynn Drainoni and Allan Walkey, will facilitate a lively discussion on the study design, methods, and implications for research and practice. Learn More
|
|
|
|
|
Secrets of Early Career Funding
Success: A Faculty Panel
Dec. 1, 2021, 3 - 4 pm
Investigators can expect to leave this session with valuable information on how to be competitive for early career funding - such as the right time to apply, the types of projects funders are looking for, ways to stand out in a large group of applicants, and more. Learn More
|
|
|
|
|
The Funding Acknowledgement |
|
|
|
|
The Funding Acknowledgement guides recipients of BU CTSI services, resources, or funding for projects or research through the grant citation process. All recipients are required to cite our grant number in associated presentations and journal publications.
|
|
|
|
|
|
|
|
|
